TABLE 1.
Demographic and Clinical Characteristics of NSCLC Cohort by Treatment Group
| Characteristic | Doublets n = 1,088 | Pem-based n = 279 | P Valuea | Pem + Bev-based n = 38 | P Value | Bev-based n = 167 | P Value | Singlets n = 114 | P Value | TKI n = 395 | P Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, mean (SD) | 66.3 (± 9.5) | 66.3(± 10.3) | 0.924 | 60.7 (± 9.0) | < 0.001 | 64.4 (± 9.6) | 0.019 | 73.1 (± 9.9) | < 0.001 | 69.6(± 12.0) | < 0.001 |
| Gender, n (%) | |||||||||||
| Male | 597 (54.9) | 145 (52.0) | 0.386 | 20 (52.6) | 0.785 | 95 (56.9) | 0.626 | 63 (55.3) | 0.936 | 144 (36.5) | < 0.001 |
| Female | 491 (45.1) | 134 (48.0) | 18 (47.4) | 72 (43.1) | 51 (44.7) | 251 (63.5) | |||||
| Race, n (%) | |||||||||||
| White | 734 (67.5) | 172 (61.7) | 0.254 | 21 (55.3) | 0.089 | 106 (63.5) | 0.024 | 81 (71.1) | 0.563 | 209 (52.9) | < 0.001 |
| Black | 135 (12.4) | 42 (15.1) | 6 (15.8) | 16 (9.6) | 14 (12.3) | 27 (6.8) | |||||
| Asian | 113 (10.4) | 35 (12.5) | 9 (23.7) | 30 (18.0) | 13 (11.4) | 120 (30.4) | |||||
| Hispanic | 94 (8.6) | 29 (10.4) | 2 (5.3) | 11 (6.6) | 6 (5.3) | 36 (9.1) | |||||
| Other/unknown | 12 (1.1) | 1 (0.4) | 0 (0.00) | 4 (2.4) | 0 (0.00) | 3 (0.8) | |||||
| Region, n (%) | |||||||||||
| South | 378 (34.7) | 127 (45.5) | 0.001 | 21 (55.3) | 0.009 | 72 (43.1) | 0.036 | 39 (34.2) | 0.910 | 154 (39.0) | 0.132 |
| North | 710 (65.3) | 152 (54.5) | 17 (44.7) | 95 (56.9) | 75 (65.8) | 241 (61.0) | |||||
| AJCC stage, n (%) | |||||||||||
| IIIB | 229 (21.1) | 20 (7.2) | < 0.001 | 4 (10.5) | 0.116 | 20 (12.0) | 0.006 | 17 (14.9) | 0.122 | 41 (10.4) | < 0.001 |
| IV | 859 (79.0) | 259 (92.8) | 34 (89.5) | 147 (88.0) | 97 (85.1) | 354 (89.6) | |||||
| Histology, n (%) | |||||||||||
| Squamous | 272 (25.0) | 2 (0.7) | < 0.001 | 1 (2.6) | 0.002 | 4 (2.4) | < 0.001 | 19 (16.7) | 0.048 | 16 (4.1) | < 0.001 |
| Nonsquamous | 816 (75.0) | 277 (99.3) | 37 (97.4) | 163 (97.6) | 95 (83.3) | 379 (96.0) | |||||
| Subsequent therapy, n (%) | |||||||||||
| No | 538 (49.5) | 113 (40.5) | 0.008 | 14 (36.8) | 0.127 | 55 (32.9) | < 0.001 | 65 (57.0) | 0.124 | 254 (64.3) | < 0.001 |
| Yes | 550 (50.6) | 166 (59.5) | 24 (63.2) | 112 (67.1) | 49 (43.0) | 141 (35.7) | |||||
| Charlson score, mean (SD) | 1.06 (± 1.5) | 0.98 (± 1.5) | 0.420 | 0.79 (± 1.5) | 0.266 | 0.83 (± 1.4) | 0.059 | 1.47 (± 1.8) | 0.020 | 1.11 (± 1.6) | 0.622 |
| Smoking status, n (%) | |||||||||||
| Current smoker | 133 (12.2) | 20 (7.2) | 0.005 | 1 (2.6) | < 0.001 | 11 (6.6) | < 0.001 | 8 (7.0) | 0.160 | 19 (4.8) | < 0.001 |
| Never smoked | 161 (14.8) | 59 (21.2) | 15 (39.5) | 43 (25.8) | 14 (12.3) | 198 (50.1) | |||||
| Past smoker | 794 (73.0) | 200 (71.7) | 22 (57.9) | 113 (67.7) | 92 (80.7) | 178 (45.1) | |||||
aP values are compared with doublets.
AJCC = American Joint Committee on Cancer; Bev = bevacizumab; NSCLC = non-small cell lung cancer; Pem = pemetrexed; TKI = tyrosine-kinase inhibitor; SD = standard deviation.